Stockscreener 앱 받기
19.97
6.59%
-1.41
Lb Pharmaceuticals Inc 주식(LBRX)의 최신 뉴스
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 5.5%What's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 7.7%Time to Buy? - MarketBeat
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Sahm
LB Pharmaceuticals (NASDAQ:LBRX) Coverage Initiated at Roth Capital - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Roth Capital - MarketBeat
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential - Investing.com Australia
Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential By Investing.com - Investing.com South Africa
PR News | On the Move: The Trevor Projects Names Wong CCOThu., Jan. 8, 2026 - O'Dwyer's PR
Poplar’s $50 million Series A to ‘transform treatment of atopic diseases’ - The Pharma Letter
LB Pharmaceuticals appoints two executives to leadership team By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Appoints Ellen Rose and Lindsay Beaupre as Senior Vice Presidents - citybiz
LB Pharmaceuticals appoints two executives to leadership team - Investing.com India
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture - The Manila Times
Stifel maintains LB Pharmaceuticals (LBRX) buy recommendation - MSN
Schizophrenia drug developer LB Pharma jumps in trading debut - MSN
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 7.7%Should You Sell? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 3.8%Here's Why - MarketBeat
Top financings 2025 - BioWorld MedTech
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - 1470 & 100.3 WMBD
Pai Panandiker Kaya Kamlesh Net Worth (2025) - GuruFocus
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000 Index - marketscreener.com
LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000E Index - MarketScreener
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Up 5.6%What's Next? - MarketBeat
LB Pharmaceuticals Earnings Notes - Trefis
[Form 4] LB PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
LB Pharmaceuticals added to Russell 2000 and 3000 Indexes - MSN
LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Lexicon publishes preclinical data validating ACSL5 as obesity target By Investing.com - Investing.com Nigeria
LB Pharmaceuticals (Nasdaq: LBRX) issues inducement equity grant to incoming CCO - Stock Titan
LB Pharmaceuticals (LBRX) Stock Analysis Report | Financials & Insights - Benzinga
Lexicon publishes preclinical data validating ACSL5 as obesity target - Investing.com
LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.8%Here's Why - MarketBeat
LB Pharmaceuticals Added to Russell 2000, 3000 Indices - marketscreener.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices - Investing.com
LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices By Investing.com - Investing.com Canada
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices - marketscreener.com
LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 6.2%Still a Buy? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighHere's What Happened - MarketBeat
LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView
LB Pharmaceuticals Inc (LBRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives $30.50 Average PT from Brokerages - Defense World
4.73%
0.92%
자본화:
|
볼륨(24시간):